Radiation therapy for urologic malignancies in the elderly

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 643-652

  Sandhu, Ajay ^a   Mundt, Arno J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Elderly; Radiotherapy; Urologic malignancies

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; BRACHYTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; GERIATRIC CARE; HUMAN; IMAGING SYSTEM; KIDNEY CARCINOMA; PENIS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; QUALITY OF LIFE; REVIEW; TESTIS TUMOR; URETHRA CANCER;

AGED; AGED, 80 AND OVER; AGING; BRACHYTHERAPY; DECISION MAKING; EVIDENCE-BASED MEDICINE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PENILE NEOPLASMS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 70350494980     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.019     Document Type: Review

References (74)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000) 181-200
3. Sandhu A., and Mundt A. Radiation therapy for older cancer patients. Aging Health 2 (2006) 919-930
4. Vulto A., Lemmens V., Louwman M., et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in south Netherlands, 1995 to 2002. Cancer 106 (2006) 2734-2742
5. Dandapani S., and Sanda M. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol 18 (2008) 67-72
6. Harris R., and Lohr K.N. Screening for prostate cancer: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (2002) 917-929
7. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283 (2000) 354-360
8. Hamilton A.S., Stanford J.L., Gilliland F.D., et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 (2001) 2517-2526
9. Hoffman R., and Barry M. Health Outcomes in Older Men Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. AJM 119 (2006) 418-425
10. Jayadevappa R., and Chhatre S. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU Int 97 (2006) 955-962
11. Alibhai S.M., Naglie G., Nam R., et al. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 21 (2003) 3318-3327
12. Houterman S., Janssen M., Verheij K., et al. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: An in-depth population-based study. Prostate Cancer Prostatic Dis 9 (2006) 179-184
13. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
14. Wong Y., Mitra N., and Hudes G. Survival associated with treatment vs. observation of localized prostate cancer. JAMA 296 (2006) 2683-2693
15. Tward J., Lee C., Pappas L., et al. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: Impact of age at diagnosis. Cancer 107 (2006) 2392-2400
16. Nguyen T., and Portman P. The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: A rare cancer network retrospective study. Radiother Oncol 77 (2005) 286-289
17. Geinitz H., and Zimmerman F. 3D conformal radiation therapy for prostate cancer in elderly patients. Radiother Oncol 76 (2005) 27-34
18. Jani A., Parikh S., Vijayakumar S., et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 65 (2005) 1157-1162
19. Huguenin P.U., Bitterli M., Lutolf U.M., et al. Localized prostate cancer in elderly patients. Outcome after radiation therapy compared to matched younger patients. Strahlenther Onkol 175 (1999) 554-558
20. Ogawa K., Nakamura K., Onishi H., et al. Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer. Anticancer Res 26 (2006) 1319-1326
21. Bolla M., Collete L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360 (2002) 103-106
22. Pilepich M., Winter K., John M., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
23. Valicenti R.K., Winter K., Cox J., et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys 57 (2003) 614-620
24. Efstathiou J., Bae K., Shipley W., et al. Goserelin not related to increased risk for CV death. Proceedings of the 2008 Genitourinary Cancers Symposium. San Francisco, (CA) (February, 2008) [Abstract 11]
25. D'Amico A., Chen M., Renshaw A., et al. Comorbidities affect benefit of combined radiation, androgen suppression. Proceedings of the 2008 Genitourinary Cancers Symposium. San Francisco, (CA) (February, 2008) [Abstract 13]
26. Chen A., D'Amico A., Neville B., et al. Patient and treatment factors associated with complications after brachytherapy. J Clin Oncol 24 (2006) 5298-5304
27. Soto D., and McLaughlin P. Combined permanent implant and external-beam radiation therapy for prostate cancer. Semin Radiat Oncol 18 (2008) 23-34
28. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. A randomized clinical trial. JAMA 296 (2006) 2329-2335
29. Bolla M., von Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy. A randomized controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
30. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy (RT) vs, wait and see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 23 (2005) 381 [Abstract 4513]
31. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in post-prostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
32. Sandhu A., Sethi R., Rice R., et al. Prostate bed localization with image-guided approach using on-board imaging: Reporting acute toxicity and implications for radiation therapy planning following prostatectomy. Radiother Oncol 88 (2008) 20-50
33. Xing L., Wu Q., Yang Y., et al. the physics of IMRT. In: Mundt A.J., and Roeske J.C. (Eds). Intensity Modulated Radiation Therapy: A Clinical Perspective (2005), BC Decker, Hamilton, Ontario 20-52
34. Meerleer G., Vakaet L., Meersschout S., et al. Intensity modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 144 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
35. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 138-140
36. Teh B.S., Wei-Yuan M., Augspurger M.E., et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: More favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 465-472
37. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomized controlled trial. Lancet Oncol 8 (2007) 475-487
38. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multi-center randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
39. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
40. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
41. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
42. Cahlon O., Zelefsky M.J., Shippy A., et al. Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes. Int J Radiat Oncol Biol Phys 66 Suppl 1 (2006) S33 [Abstract]
43. Song W., Schaly B., Bauman G., et al. Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: A radiobiological analysis. Int J Radiat Oncol Biol Phys 64 (2006) 289-300
44. Smitsman M., De Bois J., Sonke J., et al. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 975-984
45. Jani A.B., Gratzle J., Muresan E., et al. Analysis of acute toxicity with the use of transabdominal ultrasonography for prostate positioning during intensity modulated radiotherapy. Urol 65 (2005) 504-508
46. Nichol A., Chung P., Lockwood G., et al. A phase II trial of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
47. Nath S.K., Sandhu A.P., Rose B.S., et al. Toxicity analysis in post-operative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) (in press)
48. Kupelian P., Willoughby T., Mahadevan A., et al. Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67 (2007) 1088-1098
49. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
50. Pawlicki T., Cotrutz C., and King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol 40 (2007) 395-406
51. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104
52. Miles E., and Lee W. Hypofractionation for prostate cancer: A critical review. Semin Radiat Oncol 18 (2008) 41-47
53. Vargas C., Fryer A., Mahajan C., et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 744-751
54. Trofinov A., Nguyen P.L., Coen J.J., et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 69 (2007) 444-453
55. Slater J.D., Rossi Jr. C.J., Yonemoto L.T., et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 (2004) 348-352
56. Rossi Jr. C.J. Conformal proton beam radiation therapy for prostate cancer: Concepts and clinical results. Commun Oncol 4 (2007) 235-240
57. Hindson B., Turner S., and Do V. Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Austral Radiol 51 (2007) 584-588
58. Steenland E., Leer J.W., van Houwelingen H., et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastases study. Radiother Oncol 52 (1999) 101-109
59. Quitly P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31 (1994) 33-40
60. 153Sm-ethyleneddiaminetetramethrylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33 (1997) 1583-1591
61. Foell K., Martens M., and Izawa J.I. Rare case of classic testicular seminoma in an 86-year-old shows similar proliferation rate as in younger men. Urology (2007) 1007.e7-1007.e9
62. Rentinck M.E.M., Nieboer P., Sleijfer D.T.H., et al. Chemotherapy for metastatic seminoma in elderly patients. Anticancer Res 23 (2003) 3093-3096
63. Gori S., Porrozzi S., Roila F., et al. Germ cell tumors of the testis. Crit Rev Oncol Hematol 53 (2005) 141-164
64. Visco C., Medeiros L.J., Mesina O.M., et al. Non-Hodgkin's lymphoma affecting the testis: Is it curable with doxorubicin-based therapy?. Clin Lymphoma 2 (2001) 40-46
65. Miedler J., and MacLennan G. Primary testicular lymphoma. J Urol 178 (2007) 2645
66. Zouhair A., Weber D., Belkacémi Y., et al. Outcome and patterns of failure in testicular lymphoma: A multicenter rare cancer network study. Int J Radiat Oncol Biol Phys 52 (2002) 652-656
67. Shipley W., Kaufman D., Tester W., et al. An overview of bladder cancer trials in the Radiation Therapy Oncology Group (RTOG). Cancer 15 Suppl (2003) 2119
68. Muren L.P., Redpath A.T., Lord H., et al. Image-guided radiotherapy of bladder cancer: Bladder volume variation and its relation to margins. Radiother Oncol 84 (2007) 307-313
69. Kotwal S., Choudhury A., Johnston C., et al. Similar outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 70 (2008) 456-463
70. Kao G., Malkowicz S., Whittington R., et al. Locally advanced renal cell carcinoma: Low complication rate and efficacy of post-nephrectomy radiation therapy planned with CT. Radiol 193 (1994) 725-730
71. Doh L., Amato R., Paulino A., et al. Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology 20 (2006) 603-613
72. Kavanagh B., McGarry R., and Timmerman R. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16 (2006) 77-84
73. Ozsahin M., Jichlinski P., Weber D., et al. Treatment of penile cancer: To cut or not to cut. Int J Radiat Oncol Biol Phys 6 (2006) 674-679
74. Solsona E., Algaba F., Horenblas S., et al. EAU guidelines on penile cancer. Eur Urol 46 (2004) 1-8